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AA

:   amino acids

BCS

:   body condition score

CKD

:   chronic kidney disease

EAA

:   essential amino acids

GFR

:   glomerular filtration rate

MCS

:   muscle condition score

NEAA

:   nonessential amino acids

OSU‐VMC

:   Ohio State University Veterinary Medical Center

PEW

:   protein‐energy wasting

PLN

:   protein‐losing nephropathy

SSA

:   sulfasalicylic acid

UPC

:   urine protein : creatinine

1. INTRODUCTION {#jvim15436-sec-0007}
===============

Proteinuria is both a contributor to and a complication of chronic kidney disease (CKD), and it is associated with progression of disease and decreased survival in dogs and cats with kidney disease.[1](#jvim15436-bib-0001){ref-type="ref"}, [2](#jvim15436-bib-0002){ref-type="ref"} Whereas dietary protein restriction is not recommended for early stages of CKD, reducing dietary protein is almost invariably recommended in nonazotemic proteinuric dogs to decrease proteinuria.[3](#jvim15436-bib-0003){ref-type="ref"}, [4](#jvim15436-bib-0004){ref-type="ref"}, [5](#jvim15436-bib-0005){ref-type="ref"}, [6](#jvim15436-bib-0006){ref-type="ref"} Therefore, dogs with proteinuria are particularly predisposed to malnutrition, and optimal methods of nutritional management specific for this form of renal disease are needed. In people, both proteinuria and the inflammation associated with chronic disease can contribute to protein‐energy wasting (PEW), resulting in accelerated loss of lean body mass that can also adversely affect morbidity and mortality.[7](#jvim15436-bib-0007){ref-type="ref"}

Amino acid (AA) profiles are altered in dogs, cats, and humans with CKD.[8](#jvim15436-bib-0008){ref-type="ref"}, [9](#jvim15436-bib-0009){ref-type="ref"}, [10](#jvim15436-bib-0010){ref-type="ref"} Nonessential amino acids (NEAA) increase while essential amino acids (EAA) decrease in CKD, as compared to healthy control subjects.[10](#jvim15436-bib-0010){ref-type="ref"}, [11](#jvim15436-bib-0011){ref-type="ref"}, [12](#jvim15436-bib-0012){ref-type="ref"} Without adequate concentrations of EAA, animals cannot meet physiologic demands for protein synthesis, thus contributing to decreased albumin concentrations, impaired immune function, and loss of lean muscle mass. In addition to measuring absolute plasma concentrations, ratios comparing EAA and NEAA have been used in people to assess AA status.[12](#jvim15436-bib-0012){ref-type="ref"}, [13](#jvim15436-bib-0013){ref-type="ref"} The alterations in AA in CKD are because of alterations in nitrogen metabolism, tubular filtration, reabsorption, and excretion as well as increased inflammation.[12](#jvim15436-bib-0012){ref-type="ref"}, [14](#jvim15436-bib-0014){ref-type="ref"}

Information on AA status in dogs with protein‐losing nephropathy (PLN) is lacking in the literature, yet it might impact optimal management of dogs with PLN. The goal of our study was to characterize plasma AA profiles in dogs with PLN. We hypothesize that dogs with PLN will have altered plasma AA profiles as compared to healthy dogs.

2. MATERIALS AND METHODS {#jvim15436-sec-0008}
========================

2.1. Case selection criteria {#jvim15436-sec-0009}
----------------------------

Client‐owned dogs diagnosed with renal proteinuria were prospectively recruited from the dogs referred to The Ohio State University Veterinary Medical Center (OSU‐VMC) between January 2014 and July 2015. Causes of prerenal and postrenal proteinuria such as hyperadrenocorticism, cystoliths, or urinary neoplasia were excluded to the best of the attending clinicians\' assessment. All dogs had a urine culture performed. Abdominal ultrasound examination was performed in most dogs (n = 21). Proteinuria was quantified by a urine protein : creatinine (UPC) ratio using turbidimetric (protein) and Jaffe (creatinine) methods, respectively. Dogs with a UPC \> 1.5 were included. Dogs \<1 year of age and dogs diagnosed with concurrent diseases known to affect AA status or proteinuria such as protein‐losing enteropathy, hyperadrenocorticism, or urinary tract infection were excluded. Dogs that had clinical signs or ultrasonographic changes consistent with hyperadrenocorticism were excluded. Specific infectious disease testing was determined by the managing clinician.

Dogs enrolled as controls were deemed healthy on the basis of a physical examination, CBC, serum biochemistry profile, and urinalysis. The OSU‐VMC Institutional Animal Care and Use Committee approved the protocol, and all owners signed a consent form before dogs were enrolled in the study.

2.2. Study design {#jvim15436-sec-0010}
-----------------

Each dog had a physical examination performed, including body weight, body condition score (BCS; on a 1‐9 scoring system) and muscle condition score (MCS; using normal, mild, moderate, or severe scores).[15](#jvim15436-bib-0015){ref-type="ref"} All BCS and MCS scoring were done by 1 author (V. J. Parker). A Doppler systolic blood pressure was measured. Blood was collected via jugular venipuncture and urine was collected via cystocentesis for CBC, serum biochemistry profile, urinalysis, urine culture, and UPC.

Heparinized plasma was collected for AA analysis. After collection, the plasma was mixed in a 1 : 1 ratio with 6% sulfasalicylic acid and sat for 20 minutes. This mixture was then centrifuged at 14 000 rpm (22 132 rcf) for 25 minutes. The supernatant was removed and frozen at −80°C.

2.3. AA analysis {#jvim15436-sec-0011}
----------------

Plasma AA concentrations were measured with an automated high‐performance liquid chromatography AA analyzer (Biochrom 30; Biochrom Ltd, Holliston, Massachusetts) using a method described elsewhere (Kim 1995).[16](#jvim15436-bib-0016){ref-type="ref"}

2.4. Data analysis {#jvim15436-sec-0012}
------------------

The nonparametric Wilcoxon rank sum test was used to compare the AA profiles of PLN and control dogs. The Holm‐Bonferroni method was used to control the type I error at a familywise rate of 5%. Data are presented as median and range. *P*‐values \<.05 were considered significant. Sums of EAA and NEAA were calculated. Ratios of EAA‐to‐NEAA, valine‐to‐glycine, tyrosine‐to‐phenylalanine, and glycine‐to‐serine were compared between PLN and control dogs. Statistical analysis was performed using R 3.4.4 (R Core Team \[2018\]; Vienna, Austria).

3. RESULTS {#jvim15436-sec-0013}
==========

Thirty dogs with PLN and 10 control dogs were enrolled. Median age for PLN dogs was 9.4 years (range, 3.1‐14.3 years). Median age for control dogs was 4.3 years (range, 1.4‐10.3 years). Dogs with PLN were significantly older than control dogs (*P* \< .001). Breeds most represented among PLN dogs were mixed breed (n = 5), Labrador Retriever (n = 3), Fox Terrier (n = 3), Yorkshire Terrier (n = 3). There were 2 Cocker Spaniels, 2 Shetland Sheepdogs, 2 Miniature Schnauzers, 1 each of the following breeds: Akita, Australian Shepherd, Bichon Frise, Chihuahua, Cavalier King Charles Spaniel, Doberman, Golden Retriever, Malamute, Soft Coated Wheaten Terrier, and Welsh Terrier. Eleven castrated male and 19 spayed female dogs were included. Control dogs included mixed breed (n = 4), American Pit Bull Terrier (n = 3), German Shepherd (n = 2), and Rottweiler (n = 1). Six dogs were castrated males and 4 were spayed females.

Median body weight of PLN dogs was 12.9 kg (range, 2.0‐70.3 kg). With the 9‐point scoring system, median BCS was 7 (range, 4‐9). Five dogs had an ideal BCS (4, 5), and 25 dogs were overconditioned (BCS \> 5), with 8 dogs characterized as obese (BCS 8‐9). The MCS was assessed to be normal in 24 dogs. Muscle loss was noted to be mild in 4 dogs and moderate in 2 dogs. Median body weight of control dogs was 26.2 kg (range, 13.5‐47.0 kg). Median BCS was 6 (range, 4.5‐8). All control dogs had normal MCS.

Pertinent laboratory values from the PLN and control cohorts are presented in Table [1](#jvim15436-tbl-0001){ref-type="table"}. According to the IRIS CKD staging system, dogs were classified as stage 1 (n = 23), stage 2 (n = 1), stage 3 (n = 6). Median UPC was 4.8 (range, 1.7‐27.5). Eleven PLN dogs had hypoalbuminemia (\<2.9 g/dL), and the median UPC of these dogs was 7.1 (range, 4.2‐27.5). None of the control dogs was proteinuric or hypoalbuminemic. One dog had an increased systolic blood pressure of 180 mm Hg. No specific underlying etiology was determined to account for this canine hypertension.

###### 

Laboratory variables of dogs with protein‐losing nephropathy (PLN) and healthy dogs

  Laboratory variable and reference range   PLN (n = 30)          Control (n = 10)      *P*‐value
  ----------------------------------------- --------------------- --------------------- -----------
  BUN (5‐20 mg/dL)                          21 (6‐58)             19 (14‐23)            .98
  Creatinine (0.6‐1.6 mg/dL)                0.8 (0.5‐2.7)         1.0 (0.8‐1.2)         .82
  Phosphorus (3.2‐8.1 mg/dL)                3.9 (2.5‐8.1)         4.0 (2.7‐5.6)         .98
  Albumin (2.9‐4.2 g/dL)                    3.2 (0.9‐4.1)         3.7 (3.0‐4.0)         .06
  USG                                       1.018 (1.007‐1.065)   1.043 (1.031‐1.053)   \<.001
  UPC                                       4.8 (1.7‐27.5)        0.1 (0.1‐0.1)         \<.001
  BP (mm Hg)                                155 (120‐240)         137 (100‐180)         .15

Results are presented as median (range).

Abbreviations: BUN, blood urea nitrogen; UPC, urine protein : creatinine; USG, urine‐specific gravity.

All PLN dogs were eating commercial diets with a wide range of dietary protein concentrations. Only 4 dogs were eating a diet specifically designed for dogs with kidney disease. Eighteen dogs were receiving medications to inhibit the renin‐angiotensin‐aldosterone system. Eight dogs were receiving fish oil supplements. Five dogs were also receiving glucosamine/chondroitin.

3.1. AA profiles {#jvim15436-sec-0014}
----------------

Results of complete AA profiles are in Table [2](#jvim15436-tbl-0002){ref-type="table"}. Compared to control dogs, PLN dogs had significantly lower concentrations of several EAA (leucine, threonine, histidine; Figure [1](#jvim15436-fig-0001){ref-type="fig"}) and NEAA (glycine, proline, asparagine, tyrosine, o‐hydroxyproline, and serine; Figure [2](#jvim15436-fig-0002){ref-type="fig"}). Sums of both EAA and NEAA were significantly lower in PLN dogs as compared to control dogs. The AA concentrations were not significantly different between dogs based on serum albumin concentrations or severity of proteinuria.

###### 

Amino acid profiles of dogs with protein‐losing nephropathy (PLN) and control dogs

  Plasma amino acid (nMol/mL)   PLN (n = 30)         Control (n = 10)   *P*‐value
  ----------------------------- -------------------- ------------------ -----------
  EAA                                                                   
  Threonine                     201 (81‐351)         277 (200‐477)      \<.01
  Valine                        186 (113‐407)        224 (200‐423)      .13
  Methionine                    64 (27‐141)          89 (61‐230)        .13
  Isoleucine                    71 (37‐171)          80 (73‐144)        .33
  Leucine                       138 (79‐327)         243 (206‐287)      \<.01
  Phenylalanine                 80 (4‐129)           76 (63‐98)         .90
  Lysine                        210 (97‐422)         201 (126‐329)      .90
  Histidine                     83 (52‐246)          102 (80‐143)       \<.05
  Tryptophan                    59 (2‐116)           87 (63‐189)        .05
  Arginine                      105 (73‐230)         142 (130‐287)      .13
  Sum of EAA                    1244 (747‐2282)      1558 (1338‐2370)   \<.01
  NEAA                                                                  
  Taurine                       126 (1‐263)          111 (100‐158)      0.99
  Aspartic acid                 13 (6‐19)            13 (9‐19)          0.99
  Serine                        113 (57‐214)         178 (129‐268)      .02
  Asparagine                    58 (32‐126)          96 (75‐146)        \<.001
  Glutamic acid                 54 (26‐84)           51 (36‐100)        0.99
  Glutamine                     785 (441‐1352)       829 (628‐1349)     0.99
  Glycine                       198 (125‐322)        372 (322‐490)      \<.001
  Alanine                       521 (174‐1207)       587 (480‐702)      0.99
  Citrulline                    81 (25‐218)          77 (53‐126)        0.99
  Cystine                       39 (6‐80)            39 (23‐54)         0.99
  Tyrosine                      40 (8‐88)            67 (49‐85)         \<.01
  Homocysteine                  2 (0‐10)             2 (0‐3)            0.99
  Ornithine                     22 (8‐40)            22 (15‐34)         0.99
  1‐Methylhistidine             20 (6‐95)            20 (7‐29)          0.99
  3‐Methylhistidine             22 (6‐69)            12 (11‐20)         .11
  O‐Hydroxyproline              12 (0‐71)            58 (9‐110)         \<.01
  Proline                       185 (82‐381)         408 (324‐560)      \<.001
  Sum of NEAA                   2317 (1552‐23 860)   2928 (2507‐3742)   .02
  Ratios                                                                
  Valine : glycine              0.93 (0.42‐2.46)     0.60 (0.45‐1.13)   \<.01
  Tyrosine : phenylalanine      0.52 (0.34‐0.83)     0.92 (0.76‐1.02)   \<.01
  Glycine : serine              1.61 (1.01‐2.87)     2.13 (1.63‐2.67)   .03
  Sum EAA : sum NEAA            0.52 (0.39‐0.81)     0.54 (0.45‐0.65)   .79

Results are presented as median (range). Holm‐Bonferroni adjusted *P*‐values reported.

Abbreviations: EAA, essential amino acids; NEAA, nonessential amino acids; PLN, protein‐losing nephropathy.

![Selected EAA in PLN and control dogs. Each dot represents a dog. The boxes represent the 25th and 75th percentiles, and the central lines in the boxes represent the median values. The whiskers extend up to 1.5× IQR below and above the 25th and 75th percentiles, respectively. Points above and below the whiskers are indications for outlier values. The PLN dogs had lower concentrations (*P* \< .05) of EAA compared to the control dogs. EAA, essential amino acids; IQR, interquartile range; PLN, protein‐losing nephropathy](JVIM-33-680-g001){#jvim15436-fig-0001}

![Selected NEAA in dogs with PLN and control dogs. Each dot represents a dog. The boxes represent the 25th and 75th percentiles, and the central lines in the boxes represent the median values. The whiskers extend up to 1.5× IQR below and above the 25th and 75th percentiles, respectively. Points above and below the whiskers are indications for outlier values. The dogs with PLN had lower NEAA concentrations (*P* \< .05). IQR, interquartile range; NEAA, nonessential amino acids; PLN, protein‐losing nephropathy](JVIM-33-680-g002){#jvim15436-fig-0002}

Dogs with PLN had significantly lower ratios of tyrosine‐to‐phenylalanine (*P* \< .001) and glycine‐to‐serine (*P* \< .05) and a significantly greater ratio of valine‐to‐glycine (*P* \< .01). (Figure [3](#jvim15436-fig-0003){ref-type="fig"}) There was no significant difference of EAA‐to‐NEAA ratios between cohorts.

![Ratios of amino acids in dogs with PLN and control dogs. Each dot represents a dog. The boxes represent the 25th and 75th percentiles, and the central lines in the boxes represent the median values. The whiskers extend up to 1.5× IQR below and above the 25th and 75th percentiles, respectively. Points above and below the whiskers are indications for outlier values. The dogs with PLN had lower glycine‐to‐serine (P \< .05) and tyrosine‐to‐phenylalanine ratios (P \< .05 and P \< 0.01, respectively) and higher valine‐to‐glycine ratios (P \< .001). IQR, interquartile range; PLN, protein‐losing nephropathy](JVIM-33-680-g003){#jvim15436-fig-0003}

4. DISCUSSION {#jvim15436-sec-0015}
=============

We found that PLN dogs have altered AA status as compared to healthy dogs, with reduced plasma concentrations of several EAA and NEAA. The results from this study are similar to other studies in dogs and cats with various forms of kidney disease. The 30 PLN dogs from this study and 9 dogs with nonproteinuric CKD from a previous study had reduced plasma serine and proline concentrations.[8](#jvim15436-bib-0008){ref-type="ref"} Our PLN group and another group of dogs (n = 11) with induced proteinuric kidney disease[17](#jvim15436-bib-0017){ref-type="ref"} both had lower plasma leucine and tyrosine concentrations, as compared to their respective control groups. Similar to cats with CKD, the dogs with PLN in this study had significantly lower plasma concentrations of glycine, proline, tyrosine, and o‐hydroxyproline, and significantly higher concentrations of 3‐methylhistidine.[9](#jvim15436-bib-0009){ref-type="ref"} Finding increased plasma 3‐methylhistidine concentrations in these PLN dogs contrasts lower concentrations in dogs with experimentally induced kidney disease.[17](#jvim15436-bib-0017){ref-type="ref"}

Similar to what has been described in other studies of human CKD, dogs with PLN had significantly lower leucine, tyrosine, and threonine concentrations, as compared to healthy controls.[11](#jvim15436-bib-0011){ref-type="ref"}, [12](#jvim15436-bib-0012){ref-type="ref"} However, there were several dissimilarities between our findings and these studies, as well as people with nephrotic syndrome in which there are significantly higher concentrations of NEAA, glutamic acid, hydroxyproline and alanine.[13](#jvim15436-bib-0013){ref-type="ref"} In people with CKD, low histidine concentrations are associated with PEW, inflammation, oxidative stress, and decreased survival.[18](#jvim15436-bib-0018){ref-type="ref"}

The kidneys express the enzyme phenylalanine hydroxylase which is responsible for conversion of phenylalanine to tyrosine.[19](#jvim15436-bib-0019){ref-type="ref"} Decreased expression of this enzyme likely explains our finding of lower plasma tyrosine concentration and tyrosine‐to‐phenylalanine ratio in the dogs with PLN. For this reason, tyrosine has been proposed to be a conditionally EAA in people with kidney disease.[19](#jvim15436-bib-0019){ref-type="ref"}

Other AA ratios that have been described to have clinical importance in humans with kidney disease are glycine : serine and valine : glycine. Both these ratios correlate with glomerular filtration rate (GFR) in humans.[20](#jvim15436-bib-0020){ref-type="ref"} The glycine : serine ratio increases and the valine : glycine ratio decreases as GFR decreases.[20](#jvim15436-bib-0020){ref-type="ref"} Because the kidney is a major site for conversion of glycine to serine, it is not unexpected that dogs with kidney disease can have both higher glycine concentrations and glycine : serine ratios.[20](#jvim15436-bib-0020){ref-type="ref"} However, we found the dogs with PLN in this study had lower plasma glycine concentrations and glycine : serine ratios than the control dogs. This might be due in part to an effect of age as glycine concentrations have been shown to decrease with age in dogs.[21](#jvim15436-bib-0021){ref-type="ref"}

In humans with CKD, plasma valine concentrations and the valine : glycine ratio decrease with more advanced CKD.[20](#jvim15436-bib-0020){ref-type="ref"}, [22](#jvim15436-bib-0022){ref-type="ref"} Many of the dogs with PLN in this study had IRIS stage 1 disease, characterized by good urine concentrating ability and normal serum creatinine concentrations, suggesting minimal reduction in GFR, although neither GFR nor symmetric dimethylarginine was measured in these dogs. The lack of difference in plasma valine concentrations between dogs with PLN and control dogs is likely explained by the predominance of early IRIS stage dogs with PLN. This, in combination with the lower plasma glycine concentrations, can explain why dogs with PLN had higher valine : glycine ratios.

Certainly, decreased protein intake and malnutrition could contribute to altered AA metabolism. It was difficult to determine what effect diet had on these results, and dogs were eating diets that had variable protein concentrations. None of the dogs was assessed to be underweight. Interestingly, despite all dogs having adequate fat stores, 6/30 (20%) of the dogs were assessed to have either mild or moderate muscle atrophy. There were 2 dogs each with a BCS of 4, 5, and 6 of 9.

The results of this study have potential implications in nutritional management of PLN. The goal of nutritional modification in dogs with PLN is to reduce dietary protein enough to decrease proteinuria but not so much as to contribute to lean body mass loss. Theoretically, this concept seems simple; however, clinically it is more challenging to accomplish. One possible approach to optimize dietary restriction of protein without contributing to muscle loss is to strategically supplement AA. In humans with PLN, feeding low protein diets with concurrent supplementation of keto acids or EAA is advantageous as it can improve protein status while minimizing nitrogen load.[23](#jvim15436-bib-0023){ref-type="ref"}, [24](#jvim15436-bib-0024){ref-type="ref"} This concept is related to the ability of keto acids to stimulate protein synthesis while inhibiting protein breakdown. This diet regimen improves hypoalbuminemia and reduces proteinuria.[23](#jvim15436-bib-0023){ref-type="ref"} Additionally, in 1 study in humans with CKD, those who received an AA supplement had lower C‐reactive protein concentrations than those who did not.[18](#jvim15436-bib-0018){ref-type="ref"}

Oral EAA supplementation for 4‐8 weeks in dogs with renal proteinuria results in increased serum albumin concentrations and body weight with no effect on UPC.[25](#jvim15436-bib-0025){ref-type="ref"} Ultimately, it remains unclear whether the lack of decrease in UPC is clinically as important as the increase in albumin and body weight.

There were a few limitations to note. The study population was not a totally homogenous group, and renal biopsy was not performed to specifically identify type of kidney disease present. We initially set out to include dogs only with stage 1 and 2 CKD to reduce the effect that more advanced azotemia might have on AA status, as cats with CKD had more pronounced AA alterations with disease progression;[9](#jvim15436-bib-0009){ref-type="ref"} however, given timing of dog recruitment, some dogs with stage 3 CKD were enrolled.

Many dogs did have abdominal ultrasound examinations performed, but dogs were not required to have this test performed. Although specific infectious disease testing was not required, there is anecdotally a low rate of tick‐borne infections seen at this teaching hospital. Unfortunately, not all dogs were fasted before sample collection, which might influence AA concentrations. None of the samples were noted to be overtly hemolyzed.

The PLN dogs did differ in age and size from the control dogs, which might bias results. We did not see significant evidence of relationship between AA levels and age or weight; nevertheless, the assumption for the absence of relationship between the AA and age and weight is needed. One study that compared plasma AA from 19 different breeds (not specified) revealed that plasma AA did change from birth to young adulthood (1‐5 years), but changes were variable, and dogs \>5 years were not assessed.[21](#jvim15436-bib-0021){ref-type="ref"}

In conclusion, we found that dogs with PLN have altered AA status as compared to healthy control dogs. It remains to be determined whether these findings correlate with disease progression, PEW, or survival.
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